Low-Dose Aspirin Label Could Pose High Commercial Hurdle For Brilinta

AstraZeneca could face a significant commercial challenge for its antiplatelet agent Brilinta (ticagrelor) if, as expected, FDA approves the drug with a recommendation for concomitant use of low-dose aspirin in acute coronary syndrome patients